Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …

Molecular glue (MG) degraders are monovalent small molecule compounds that co-opt E3
ubiquitin ligases to target neo-substrates for proteasomal degradation. Here, we provide a …

Targeted protein degradation has recently emerged as a novel option in drug discovery.
Natural protein half-life is expected to affect the efficacy of degrading agents, but to what …

Targeted protein degradation (TPD) relies on small molecules to recruit proteins to E3
ligases to induce their ubiquitylation and degradation by the proteasome. Only a few of the …

Molecular glues are proximity-inducing small molecules that have emerged as an attractive
therapeutic approach. However, developing molecular glues remains challenging, requiring …

Proteolysis-Targeting Chimeras (PROTACs) are bifunctional molecules that bring a target
protein and an E3 ubiquitin ligase into proximity to append ubiquitin, thus directing target …

Endometriosis is a debilitating, chronic inflammatory disease affecting~ 10% of reproductive
age women worldwide with no cure. While macrophages have been intrinsically linked to …

Proteolysis-targeting chimeras (PROTACs) describe compounds that bind to and induce
degradation of a target by simultaneously binding to a ubiquitin ligase. More generally …

Targeted protein degradation (TPD) is an emerging pharmacologic strategy. It relies on
small-molecule “degraders” that induce proximity of a component of an E3 ubiquitin ligase …

Class I histone deacetylases (HDACs) are closely associated with the development of a
diverse array of diseases, including cancer, neurodegenerative disorders, HIV, and …